Galapagos Boasts ''Best-In-Class'' With Its RA JAK Inhibitor
This article was originally published in Scrip
Executive Summary
Galapagos NV has thrown down the gauntlet to its rivals in the JAK inhibitor space, saying new Phase II data support a potential "best-in-class" title for its drug candidate filgotinib in rheumatoid arthritis. AbbVie Inc. now has 60 days to decide whether it wants to take up its option to license the product, something which analysts say these data make almost inevitable.